Citation Impact
Citing Papers
Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition
2013 StandoutScience
Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction
2008 Standout
Ductal Carcinoma In situ and the Emergence of Diversity during Breast Cancer Evolution
2008
TWIST1-Induced miR-424 Reversibly Drives Mesenchymal Programming while Inhibiting Tumor Initiation
2015
Gene Expression Profiles Associated with the Presence of a Fibrotic Focus and the Growth Pattern in Lymph Node–Negative Breast Cancer
2008
PARP inhibitors: Synthetic lethality in the clinic
2017 StandoutScience
Descriptive analysis of estrogen receptor (ER)‐negative, progesterone receptor (PR)‐negative, and HER2‐negative invasive breast cancer, the so‐called triple‐negative phenotype
2007 Standout
Molecular Stratification of Triple-Negative Breast Cancers
2011
Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells
2008
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
2017 Standout
Triple negative breast cancer: unmet medical needs
2010
Comprehensive molecular portraits of human breast tumours
2012 StandoutNature
Mesenchyme Forkhead 1 ( FOXC2 ) plays a key role in metastasis and is associated with aggressive basal-like breast cancers
2007
Epithelial–mesenchymal transition in breast cancer correlates with high histological grade and triple‐negative phenotype
2012
Triple negative tumours: a critical review
2007
Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy
2016
Phase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2+ Breast Cancer
2016
The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas
2008
Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial
2018
Triple-Negative Breast Cancer: An Unmet Medical Need
2011
Hypoxia induces the breast cancer stem cell phenotype by HIF-dependent and ALKBH5-mediated m 6 A-demethylation of NANOG mRNA
2016 StandoutNobel
Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers
2007
The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes
2007 Standout
A 3′-untranslated region KRAS variant and triple-negative breast cancer: a case-control and genetic analysis
2011
The Evolution of Triple-Negative Breast Cancer: From Biology to Novel Therapeutics
2016
Prognostic impact of circulating tumor cell apoptosis and clusters in serial blood samples from patients with metastatic breast cancer in a prospective observational cohort
2016
Triple-Negative Breast Cancer: Correlation between MR Imaging and Pathologic Findings
2009
Triple-Negative Breast Cancer
2010 Standout
The PI3K/AKT Pathway as a Target for Cancer Treatment
2015
Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype
2008 Standout
Cancer statistics, 2020
2020 Standout
The RNA Binding Protein Quaking Regulates Formation of circRNAs
2015 Standout
Elements of cancer immunity and the cancer–immune set point
2017 StandoutNature
The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade
2009
Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis
2007
Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput Screening
2009 Standout
Molecular mechanisms of epithelial–mesenchymal transition
2014 Standout
A Core MYC Gene Expression Signature Is Prominent in Basal-Like Breast Cancer but Only Partially Overlaps the Core Serum Response
2009
Appraising iniparib, the PARP inhibitor that never was—what must we learn?
2013
Epithelial–mesenchymal plasticity in carcinoma metastasis
2013
HIF2α cooperates with RAS to promote lung tumorigenesis in mice
2009 StandoutNobel
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
2016 Standout
Tumor Metastasis: Molecular Insights and Evolving Paradigms
2011 Standout
EMT Transition States during Tumor Progression and Metastasis
2018 Standout
BRCA1-IRIS regulates cyclin D1 expression in breast cancer cells
2006
Longitudinally collected CTCs and CTC-clusters and clinical outcomes of metastatic breast cancer
2016
Interdependent IL-7 and IFN-γ signalling in T-cell controls tumour eradication by combined α-CTLA-4+α-PD-1 therapy
2016 StandoutNobel
Prospective assessment of the prognostic value of circulating tumor cells and their clusters in patients with advanced-stage breast cancer
2015
Epigenetics in Cancer
2008 Standout
Histological and molecular types of breast cancer: is there a unifying taxonomy?
2009
A Long Noncoding RNA Controls Muscle Differentiation by Functioning as a Competing Endogenous RNA
2011 Standout
Implications of the Hybrid Epithelial/Mesenchymal Phenotype in Metastasis
2015
Hypoxia-inducible factor–dependent breast cancer–mesenchymal stem cell bidirectional signaling promotes metastasis
2012 StandoutNobel
How basal are triple‐negative breast cancers?
2008
Quantum imaging with undetected photons
2014 StandoutNatureNobel
Tumour invasion and metastasis initiated by microRNA-10b in breast cancer
2007 StandoutNature
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
2016 Standout
An embryonic stem cell–like gene expression signature in poorly differentiated aggressive human tumors
2008 Standout
U1 snRNP regulates cancer cell migration and invasion in vitro
2020 Standout
Emerging Biological Principles of Metastasis
2017 Standout
The descriptive epidemiology of female breast cancer: An international comparison of screening, incidence, survival and mortality
2012
EMT: 2016
2016 Standout
Stochastic State Transitions Give Rise to Phenotypic Equilibrium in Populations of Cancer Cells
2011 Standout
The causes and consequences of genetic heterogeneity in cancer evolution
2013 StandoutNature
TGFβ in Cancer
2008 Standout
The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers
2007
The basics of epithelial-mesenchymal transition
2009 Standout
AKT/PKB Signaling: Navigating the Network
2017 Standout
Clonal evolution in cancer
2012 StandoutNature
Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients
2007
let-7 Regulates Self Renewal and Tumorigenicity of Breast Cancer Cells
2007 Standout
A dynamic in vivo model of epithelial-to-mesenchymal transitions in circulating tumor cells and metastases of breast cancer
2011
BRCA1 dysfunction in sporadic basal-like breast cancer
2006
Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure)
2016
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
2009 Standout
A fibrotic focus is a prognostic factor and a surrogate marker for hypoxia and (lymph)angiogenesis in breast cancer: review of the literature and proposal on the criteria of evaluation
2007
Matrix Crosslinking Forces Tumor Progression by Enhancing Integrin Signaling
2009 Standout
En Route to Metastasis: Circulating Tumor Cell Clusters and Epithelial-to-Mesenchymal Transition
2015
Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study
2006 Standout
Pancreatic cancer
2011 Standout
The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells
2008 Standout
Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas
2007
ID genes mediate tumor reinitiation during breast cancer lung metastasis
2007
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
2018 Standout
Circadian clock disruption improves the efficacy of chemotherapy through p73-mediated apoptosis
2011 StandoutNobel
Basal-Like Breast Cancer: A Critical Review
2008
Performance of Prediction Models for BRCA Mutation Carriage in Three Racial/Ethnic Groups: Findings from the Northern California Breast Cancer Family Registry
2009
Dynamic interactions between the promoter and terminator regions of the mammalian BRCA1 gene
2008
Immune targeting in breast cancer.
2015
Unmet Clinical Need: Developing Prognostic Biomarkers and Precision Medicine to Forecast Early Tumor Relapse, Detect Chemo-Resistance and Improve Overall Survival in High-Risk Breast Cancer
2020
Potential and Challenges for Mid-Infrared Sensors in Breath Diagnostics
2009
Quantitative Multiplex Methylation-Specific PCR Analysis Doubles Detection of Tumor Cells in Breast Ductal Fluid
2006
Hypoxia-inducible factor 1-dependent expression of platelet-derived growth factor B promotes lymphatic metastasis of hypoxic breast cancer cells
2012 StandoutNobel
BRCA1-IRIS promotes human tumor progression through PTEN blockade and HIF-1α activation
2018 StandoutNobel
Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future
2015
PancPRO: Risk Assessment for Individuals With a Family History of Pancreatic Cancer
2007
Global cancer statistics, 2012
2015 Standout
HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells
2015 StandoutNobel
A Randomized Phase II Study of Veliparib with Temozolomide Or Carboplatin/Paclitaxel Versus Placebo with Carboplatin/Paclitaxel in Brca1 / 2 Metastatic Breast Cancer: Design and Rationale
2016
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
2018 Standout
Breast cancer statistics, 2013
2013 Standout
Works of Rita Nanda being referenced
Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019
2015
Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): Results from I-SPY 2.
2017
Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma
2005
TBCRC 018: Phase II study of iniparib plus chemotherapy to treat triple-negative breast cancer (TNBC) central nervous system (CNS) metastases (mets).
2013
Genetic Testing in an Ethnically Diverse Cohort of High-Risk Women
2005
“Targeting” Triple-Negative Breast Cancer: The Lessons Learned From BRCA1-Associated Breast Cancers
2011
BRCA1 Promoter Methylation in Sporadic Breast Cancer Is Associated with Reduced BRCA1 Copy Number and Chromosome 17 Aneusomy
2005
Abstract S1-09: A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer
2015
Efficacy of the combination of ABT-888 (veliparib) and carboplatin in patients with BRCA-associated breast cancer.
2013
Abstract PD6-10: KEYNOTE-086 cohort B: Pembrolizumab monotherapy for PD-L1–positive, previously untreated, metastatic triple-negative breast cancer (mTNBC)
2018
“Intrinsic Gene Expression” subtypes correlated with grade and morphometric parameters reveal a high proportion of aggressive basal-like tumors among black women of African ancestry
2004
Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer
2018
“Intrinsic Gene Expression” subtypes correlated with grade and morphometric parameters reveal a high proportion of aggressive basal-like tumors among black women of African ancestry
2004
Population Differences in Breast Cancer: Survey in Indigenous African Women Reveals Over-Representation of Triple-Negative Breast Cancer
2009
Relationship between tumor infiltrating lymphocyte (TIL) levels and response to pembrolizumab (pembro) in metastatic triple-negative breast cancer (mTNBC): Results from KEYNOTE-086
2017
Abstract PD1-2: PIK3CA mutations and/or low PTEN predict resistance to combined anti-HER2 therapy with lapatinib and trastuzumab and without chemotherapy in TBCRC006, a neoadjuvant trial of HER2-positive breast cancer patients
2013
Results from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC).
2015